AKT1 and acute myeloid leukemia: Down-regulation of METTL3 expression in bone marrow mesenchymal stem cells of acute myeloid leukemia (AML) induces an increase in AKT protein, leading to enhanced mesenchymal stem cell (MSC) adipogenesis, which contributes to chemotherapy resistance of AML cells [186].